Home
Companies
Catalysts
Deep Dives
KRASCENDO-1
PHASE3
ACTIVE
n=450
Drug:
Divarasib
·
ROG.SW
Study Design
Design
Randomized, 2L+ NSCLC KRAS G12C
Enrollment
450
Treatment Arms
Primary Endpoints
[{"id":"kras-pe1","name":"Progression-Free Survival","type":"PRIMARY","unit":"HR","results":[]}]
Efficacy Results
Testing divarasib vs docetaxel in 2L+ NSCLC. Competing with Amgen sotorasib and Mirati adagrasib.
Assessment
Data expected 2026. Need to differentiate on efficacy/safety to compete.
Data from Supabase · Updated 2026-03-24